Percutaneous Coronary Intervention (PCI), a minimally invasive method for unblocking coronary arteries, is witnessing increased adoption driven by the growing incidence of heart diseases and a preference for less invasive procedures. Despite these positive trends, the market faces challenges due to infection risks. However, ongoing technological advancements present opportunities for global market leaders to further enhance PCI procedures, making them safer and more effective.
The escalating prevalence of heart diseases worldwide has fueled the demand for PCI as an effective and less invasive treatment option. Patients and healthcare professionals alike are increasingly favoring minimally invasive procedures due to their associated benefits, including reduced recovery time and lower risk of complications.
While the market for PCI is on the rise, the potential threat of infections poses a challenge to its sustained growth. Infection risks associated with medical procedures are a concern that needs to be addressed to ensure the continued acceptance of PCI. Medical professionals and researchers are actively exploring ways to mitigate these risks and enhance the safety profile of PCI.
Despite the challenges, the PCI market holds promise, driven by continuous technological advancements. Innovations in medical technology are paving the way for enhanced PCI procedures, making them more precise, efficient, and safer for patients. The integration of cutting-edge technologies into PCI, such as improved imaging techniques and advanced catheter technologies, is expected to elevate the overall success and safety of these procedures.
Global market leaders in the medical field are well-positioned to capitalize on the opportunities presented by technological advancements in PCI. Collaborations, research initiatives, and investments in innovative solutions can contribute to the development of next-generation PCI procedures. This not only addresses existing challenges but also establishes a pathway for sustained market growth.
Collaborative efforts among healthcare professionals, researchers, and industry leaders play a crucial role in navigating the evolving landscape of PCI. By fostering partnerships and investing in research and development, the global medical community can address existing challenges, enhance patient safety, and drive continuous innovation in the field. This collaborative approach not only ensures the sustainability of the PCI market but also reinforces its position as a transformative solution in the realm of cardiac interventions.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2022 | USD 8.78 Billion |
Market Size Value In 2023 | USD 15.87 Billion |
Growth Rate | 5.10%(2023-2032) |
The Percutaneous Coronary Intervention Market size was valued at USD 8.78 Billion in 2023 and is projected to grow from USD 9.55 Billion in 2024 to USD 20.53 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.03% during the forecast period (2024 - 2032).
“The percutaneous coronary intervention market is set for robust growth driven by technological advancements, increasing prevalence of cardiovascular diseases, and a rising aging population. With a focus on minimally invasive procedures and innovative stent technologies, the market is poised to witness sustained expansion, offering improved patient outcomes, and contributing to the evolution of interventional cardiology.”
The expected growth in the market can be attributed to the rising prevalence of heart diseases and increasing preference for minimally invasive procedures.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Over the last 30 years, the number of death and disabilities caused by cardiovascular disease has continuously increased around the world. The disorder, which includes heart disease and stroke, was responsible for one-third of the deaths across the globe in 2019. For instance, in 2019, the World Health Organiation estimated that nearly 17.9 million individuals died from cardiovascular diseases, accounting for 32% of all global fatalities. Heart attacks and strokes were responsible for 85% of these fatalities. Unhealthy food, physical inactivity, cigarette use, and problematic alcohol consumption are the most major behavioural risk factors for heart disease and stroke. Individuals may experience elevated blood pressure, elevated blood glucose, elevated blood lipids, and overweight or obesity because of behavioural risk factors. These "intermediate risks factors" may be assessed in primary care settings and suggest an elevated risk of heart attack, stroke, heart failure, and other consequences. The individuals that undergo surgery due to heart diseases are also growing. Therefore, due to the rising prevalence of heart diseases the market for global percutaneous coronary intervention will grow at a positive pace.
The Percutaneous Coronary Intervention Market segmentation, based on product type, includes coronary stents, ballon catheters, coronary guidewires, guiding catheters, guiding sheaths, diagnostic catheters, crossing catheters, inflation device, guidance system, peripheral thrombectomy system, embolic protection system, and accessories. The coronary stents segment held the majority share in the market in 2022. Moreover, the launch of the newest generation of drug-eluting catheter stents to fulfill the demand of physicians is fueling the growth of the product type segment.
The Percutaneous Coronary Intervention Market segmentation, based on vascular access, includes radial and femoral. The radial segment dominated the market in 2022. Radial PCI is a safe and effective procedure that can be used to treat a variety of coronary artery diseases. It is the preferred approach to PCI for most patients because it offers several advantages over femoral PCI. Moreover, radial PCI is becoming increasingly popular due to advantages such as reducing the risk of stroke during the procedure and shortening the duration of the hospital stay.
Figure 2: Percutaneous Coronary Intervention Market, by Vascular Access, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Percutaneous Coronary Intervention Market segmentation, based on end user, includes hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment dominated the market in 2022. This is due to factors such as the increasing number of angioplasties, rising incidences of diabetes & obesity patients may lead to coronary artery diseases.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. The North America percutaneous coronary intervention market accounted for the largest market share in 2022. North America is further divided into the US and Canada. North America held the largest market share due to the increase in demand for minimally invasive procedures, increasing prevalence of cardiovascular diseases, and unhealthy lifestyle habits propelling regional market growth over the forecast period. For instance, In the United States, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. Cardiovascular disease claims one life every 33 seconds in the US. In 2021, approximately 695,000 people in the United States died from heart disease, accounting for one in every five deaths.
Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: PERCUTANEOUS CORONARY INTERVENTION MARKET BY REGION 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe percutaneous coronary intervention market accounted for the second-largest market share due to unhealthy lifestyle habits, increasing geriatric population, and extensive R&D activities. Furthermore, the Germany percutaneous coronary intervention market is attributed to hold the largest market share, and the France percutaneous coronary intervention market is projected be the fastest growing market in the Europe region.
The Asia-Pacific percutaneous coronary intervention market is expected to be the fastest growing from 2023 to 2032 due to rising income levels, an increase in the prevalence of cardiovascular diseases, and better healthcare infrastructure. Moreover, China percutaneous coronary intervention market accounted to hold the largest market share, and the India percutaneous coronary intervention market is projected to be the fastest growing market in the Asia-Pacific region.
Percutaneous Coronary Intervention Key Market Players & Competitive Insights
The Percutaneous Coronary Intervention Market is distinguished by the presence of many global, regional, and local players. The rising prevalence of heart diseases and increasing preference for minimally invasive procedures are further expected to drive the growth of the Percutaneous Coronary Intervention Market during the forecast period. However, the risk of infection and complications during cardiac catheterization may hamper the growth of the Percutaneous Coronary Intervention Market. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their devices and signing contracts and agreements to broaden their reach and reduce operational costs. For instance, in April 2022, Boston Scientific Corporation (US) launched the Kinetix Guidewire for percutaneous coronary intervention (PCI) procedures. Guidewires are tiny, flexible wires that surgeons use to administer interventional devices like drug-eluting stents.
Boston Scientific Corporation is a well-established medical device company that is involved in the development, manufacture, and marketing of medical devices used in various interventional medical specialties. The company cooperates with healthcare professionals to create a broad portfolio of significant innovations that increase outcomes, reduce costs, and increase efficiencies. Its product portfolio is divided into interventional cardiology, endoscopy, neuromodulation, peripheral interventions, rhythm management, and urology & pelvic health. Boston Scientific Corporation's manufacturing facilities are positioned across Malaysia, the US, and Ireland. The company distributes its products in 130 countries across the world. Apart from this, it has a presence in Japan, the Netherlands, France, Poland, India, China, Turkey, South Africa, and Singapore, among others.
Moreover, In April 2022, Boston Scientific Corporation launched the Kinetix Guidewire for percutaneous coronary intervention (PCI) procedures. Guidewires are tiny, flexible wires that surgeons use to administer interventional devices like drug-eluting stents.
Key Companies in the Percutaneous Coronary Intervention market includes.
Percutaneous Coronary Intervention Industry Developments
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)